Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Kosan Biosciences was incorporated on 6th January 1995 and began operations in 1996. Kosan is a biotechnology company using its proprietary technologies to develop drug candidates from an important class of natural product compounds known as polyketides. By manipulating the genetic instructions for making polyketides, Kosan is able to create, modify and produce them in ways that chemists cannot. Kosan's primary programmes are currently directed at discovery and development of polyketides for cancer, infectious disease and gastrointestinal motility disorders.